MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
37.77
+2.43
+6.88%
After Hours: 37.67 -0.1 -0.27% 19:31 02/06 EST
OPEN
35.45
PREV CLOSE
35.34
HIGH
38.03
LOW
35.45
VOLUME
1.76M
TURNOVER
--
52 WEEK HIGH
48.26
52 WEEK LOW
1.865
MARKET CAP
4.11B
P/E (TTM)
-36.6059
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)
TipRanks · 4d ago
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
Simply Wall St · 4d ago
Terns Pharmaceuticals Grants Equity Awards to New Employees Under Inducement Plan
Reuters · 5d ago
Terns Pharmaceuticals gewährt neuen Mitarbeitern Aktienoptionen als Vergütungsanreiz
Reuters · 5d ago
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders
Simply Wall St · 6d ago
Weekly Report: what happened at TERN last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at TERN last week (0119-0123)?
Weekly Report · 01/26 09:43
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.